ThriveRx supports Crohn’s disease and ulcerative colitis consumers nationwide who receive intravenous inhibitors of tumor necrosis factor (TNF)-alpha for inflammatory conditions. These include Remicade® (infliximab), Simponi Aria® (golimumab), and biosimilars of infliximab.

TNF-alpha is a protein that helps the body regulate its immune system. Too much can lead to inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.

Intravenous TNF-alpha inhibitors can reduce inflammation and stop disease progression, relieving patients’ sometimes life-altering symptoms.

We are committed to helping you thrive while on home parenteral or enteral nutrition—including providing home administration of intravenous TNF-alpha inhibitors, securing third-party financial assistance and working on prior authorizations and appeals.

Also, our Maximize Health program helps consumers with Crohn’s and colitis through routine home monitoring, clinical support, and physician coordination. The program takes you on a carefully planned course toward intestinal rehabilitation.

We are here for consumers 24/7, ready to answer clinical questions and offer support. We do whatever it takes to help consumers manage their therapy.

Get started with ThriveRx